http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies. http://medicalxpress.com/news/2013-05-therapeutic-synergy-primary-effusion-lymphoma.html Cancer Wed, 01 May 2013 12:00:05 EST news286624931 ICREA professor Raúl Méndez publishes a study in Nature describing how the CPBE1 protein "takes the brakes off" the production of proteins associated with the cell switch from being healthy to tumorous. The study highlights CPEB proteins as promising targets, thus opening up a new and unexplored therapeutic window. The lab has developed a system for screening compounds that impede the action of CPEB proteins in tumors. http://medicalxpress.com/news/2013-02-team-mechanism-tumor.html Cancer Sun, 24 Feb 2013 13:00:39 EST news280918992 Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). http://medicalxpress.com/news/2013-02-experimental-drug-combination-lymphoma-cells.html Cancer Wed, 06 Feb 2013 12:59:47 EST news279377979 Patients whose aggressive lymphomas have relapsed or failed to respond to the current front-line chemotherapy regimen now have an effective second line of attack against their disease. Reporting the results of a first-of-its-kind phase 1 clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of Vorinostat (suberoylanilide hydroxamic acid) in combination with another round of commonly used second-line drugs resulted in a 70 percent response rate, including several patients whose lymphoma cells disappeared entirely. http://medicalxpress.com/news/2013-02-high-dose-vorinostat-effective-relapsed-lymphomas.html Cancer Mon, 04 Feb 2013 10:44:22 EST news279196997 Drugs that are used in the clinic to treat some forms of breast and kidney cancer and that work by inhibiting the signaling molecule mTORC1 might have utility in treating some of the more than 15 percent of human cancers driven by alterations in the Myc gene, according to data from a preclinical study published in Cancer Discovery, a journal of the American Association for Cancer Research. http://medicalxpress.com/news/2012-12-hard-to-treat-myc-driven-cancers-susceptible-drug.html Cancer Fri, 14 Dec 2012 10:00:01 EST news274695612 Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting. http://medicalxpress.com/news/2012-12-blood-immune-protein-hodgkin-disease.html Cancer Mon, 10 Dec 2012 16:06:29 EST news274377950 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL (ABC-DLBCL), remains a major therapeutic challenge. An international research team, led by two laboratories from Weill Cornell Medical College, has developed a new experimental drug therapy to target this aggressive form of lymphoma. http://medicalxpress.com/news/2012-12-drug-therapy-aggressive-non-hodgkin-lymphoma.html Cancer Mon, 10 Dec 2012 15:46:52 EST news274376793 A pathway called the "Unfolded Protein Response," or UPR, a cell's way of responding to unfolded and misfolded proteins, helps tumor cells escape programmed cell death during the development of lymphoma. http://medicalxpress.com/news/2012-11-pathway-human-lymphoma-blood-cancer.html Cancer Wed, 21 Nov 2012 11:47:26 EST news272720837 (Medical Xpress)—Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered the mechanism by which an experimental drug known as GCS-100 removes from lymphoma cells a protein that prevents the cells from responding to chemotherapy. http://medicalxpress.com/news/2012-10-discovery-revives-lymphoma-treatment.html Cancer Mon, 15 Oct 2012 06:04:57 EST news269499850 (Medical Xpress)—Women respond much better than men to the treatment of chronic follicular lymphoma with a monoclonal antibody that targets CD20 (rituximab). These are the findings of a multi-centre, Austria-wide study by the Arbeitsgemeinschaft medikamentöse Tumortherapie (AGMT) carried out under the supervision of the University Department of Internal Medicine I and study leader Ulrich Jäger, which has now been published in the journal Haematologica. It was also discovered that the volume of lymphoma cells has an important role to play. http://medicalxpress.com/news/2012-10-women-treatment-lymph-gland-cancer.html Cancer Wed, 10 Oct 2012 08:27:35 EST news269076437 Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse. http://medicalxpress.com/news/2012-07-potential-key-treatment-mantle-cell.html Cancer Wed, 18 Jul 2012 12:16:58 EST news261832609 (Medical Xpress) -- One of the reasons that cancer cells proliferate is that they metabolize fuel differently from normal cells.  A team led by Blossom Damania, PhD, at the University of North Carolina at Chapel Hill School of Medicine, reports that two inter-related metabolic processes contribute to cell proliferation in non-Hodgkin lymphoma. http://medicalxpress.com/news/2012-07-cell-metabolism-therapeutic.html Cancer Tue, 03 Jul 2012 07:01:20 EST news260517671 Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3. http://medicalxpress.com/news/2012-04-compound-key-mechanism-lymphoma.html Cancer Tue, 03 Apr 2012 09:41:58 EST news252664715 Scientists at the BC Cancer Agency in British Columbia, Canada and their U.S. collaborators have identified a number of new genetic mutations involved in non-Hodgkin lymphoma, or NHL. http://medicalxpress.com/news/2011-07-genetic-mutations-non-hodgkin-lymphoma.html Cancer Thu, 28 Jul 2011 04:17:46 EST news231045427 Researchers at the University of Maryland School of Medicine have discovered a novel interaction between two proteins involved in regulating cell growth that could provide possible new drug targets for treating diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma. http://medicalxpress.com/news/2011-07-drug-common-non-hodgkin-lymphoma.html Cancer Tue, 19 Jul 2011 14:10:01 EST news230300578 Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors. Now the immunologist Dr. Uta Höpken (Tumor and Immunogenetics Research Group at the Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch in the Helmholtz Association) and the hematologist Dr. Armin Rehm (Charité – Virchow-Klinikum, Department of Hematology, Oncology and Tumor Immunology, MDC) have shown for the first time that specific forms of lymphoma also create their own survival niche. http://medicalxpress.com/news/2011-06-survival-niche-cancer-cells.html Cancer Mon, 06 Jun 2011 10:03:22 EST news226573393